Cabergoline Versus Calcium Infusion in Ovarian Hyperstimulation Syndrome Prevention
Status:
Completed
Trial end date:
2017-04-15
Target enrollment:
Participant gender:
Summary
Giving oral Cabergoline or calcium infusion in women at high risk for developing ovarian
hyperstimulation syndrome in context of assisted reproductive technologies aiming in its
prevention